Roche reports positive top line Phase II data for CT-388 in obesity
Participants receiving up to 24mg of CT-388 had a placebo-adjusted weight loss of 22.5% at 48 weeks.
28 January 2026
28 January 2026
Participants receiving up to 24mg of CT-388 had a placebo-adjusted weight loss of 22.5% at 48 weeks.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.